CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion
Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion
Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions
Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million).
